Phase 1 Clinical Results for NP10679, a pH‐sensitive GluN2B‐selective N‐methyl‐d‐aspartate Receptor Inhibitor
Authors:
Open Access
- 15 January 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 12 (7) , 706-717
Abstract
NP10679 is a context‐dependent and subunit‐selective negative allosteric modulator of N‐methyl‐d‐aspartate (NMDA) receptors. It is a more potent inhibitor of GluN2B‐containing NMDA receptors at the acidic levels of extracellular pH (eg, 6.9) found in the penumbral regions associated with cerebral ischemia than at physiological pH. This property allows NP10679 to act selectively in ischemic tissue while minimizing the nonselective blockade of NMDA receptors in healthy brain, thereby reducing on‐target adverse effects. We report the results of a first‐in‐human pharmacokinetic and safety phase 1 clinical trial in healthy volunteers receiving single or multiple doses of NP10679 (NCT04007263). We found that NP10679 was well‐tolerated and with a half‐life of 20 hours, which is amenable to once per day dosing. The only notable side effect in this clinical trial was modest somnolence at higher doses, atypical in that the subject could easily be aroused. The overall results suggest that NP10679 is a candidate for further development for use in acute brain injury, such as ischemic stroke or aneurysmal subarachnoid hemorrhage, as well as for use in neuropsychiatric indications.Keywords
This publication has 36 references indexed in Scilit:
- The 2012 Feinberg LectureStroke, 2013
- Synaptic NMDA Receptors Mediate Hypoxic Excitotoxic DeathJournal of Neuroscience, 2012
- Glutamate Receptor Ion Channels: Structure, Regulation, and FunctionPharmacological Reviews, 2010
- Incidence and 10-Year Survival of Intracerebral Hemorrhage in a Population-Based RegistryStroke, 2009
- An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive DisorderJournal of Clinical Psychopharmacology, 2008
- The Effect of the Selective NMDA Receptor Antagonist Traxoprodil in the Treatment of Traumatic Brain InjuryJournal of Neurotrauma, 2005
- Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic riskBritish Journal of Pharmacology, 2004
- Selfotel in Acute Ischemic StrokeStroke, 2000
- Failure of the competitive N-methyl-d-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trialsJournal of Neurosurgery, 1999
- Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysisJournal of Neurosurgery, 1996